MedTrace Logo

Different Dermatological Approaches the Treatment of Melasma

NCT03923062 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-01-13

No results posted yet for this study

Summary

To compare the efficacy and safety of cryopeeling (using Liquid Nitrogen) and tranexemic acid (cyclokapron) versus chemical peeling (using TCA 20%) in treatment of melasma.

Conditions

  • Melasma

Interventions

DEVICE

chemicalpeeling

Cleansing and degreasing the face with alcohol . * The patients must be sitting at an angle of 45. * A 2 × 2 cm cotton gauze will be used to apply TCA 20%. * We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area. * We then will wait for a few minutes and will observe the frost developing. * The patient will be then allowed to wash her face.

DEVICE

cryopeeling

Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.

COMBINATION_PRODUCT

microneedling

Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face. * After gentle cleansing, topical analgesic cream will be applied over the area to be treated. * The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-10-01
Completion
2020-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03923062 on ClinicalTrials.gov